165 related articles for article (PubMed ID: 12235269)
1. Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration.
Anikwue R; Huffman JW; Martin ZL; Welch SP
J Pharmacol Exp Ther; 2002 Oct; 303(1):340-6. PubMed ID: 12235269
[TBL] [Abstract][Full Text] [Related]
2. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
Welch SP; Huffman JW; Lowe J
J Pharmacol Exp Ther; 1998 Sep; 286(3):1301-8. PubMed ID: 9732392
[TBL] [Abstract][Full Text] [Related]
3. Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride].
Shivachar AC; Martin BR; Ellis EF
Biochem Pharmacol; 1996 Mar; 51(5):669-76. PubMed ID: 8615904
[TBL] [Abstract][Full Text] [Related]
4. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats.
Smith FL; Fujimori K; Lowe J; Welch SP
Pharmacol Biochem Behav; 1998 May; 60(1):183-91. PubMed ID: 9610941
[TBL] [Abstract][Full Text] [Related]
5. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception.
Welch SP; Dunlow LD; Patrick GS; Razdan RK
J Pharmacol Exp Ther; 1995 Jun; 273(3):1235-44. PubMed ID: 7791096
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.
Járai Z; Wagner JA; Varga K; Lake KD; Compton DR; Martin BR; Zimmer AM; Bonner TI; Buckley NE; Mezey E; Razdan RK; Zimmer A; Kunos G
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14136-41. PubMed ID: 10570211
[TBL] [Abstract][Full Text] [Related]
7. Effects of cannabinoids on preimplantation mouse embryo development and implantation are mediated by brain-type cannabinoid receptors.
Paria BC; Ma W; Andrenyak DM; Schmid PC; Schmid HH; Moody DE; Deng H; Makriyannis A; Dey SK
Biol Reprod; 1998 Jun; 58(6):1490-5. PubMed ID: 9623610
[TBL] [Abstract][Full Text] [Related]
8. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol.
Romero J; García L; Fernández-Ruiz JJ; Cebeira M; Ramos JA
Pharmacol Biochem Behav; 1995 Aug; 51(4):731-7. PubMed ID: 7675852
[TBL] [Abstract][Full Text] [Related]
9. The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta9-tetrahydrocannabinol or anandamide.
Mallet PE; Beninger RJ
Psychopharmacology (Berl); 1998 Nov; 140(1):11-9. PubMed ID: 9862397
[TBL] [Abstract][Full Text] [Related]
10. Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics.
Fernández-Ruiz JJ; Muñoz RM; Romero J; Villanua MA; Makriyannis A; Ramos JA
Biochem Pharmacol; 1997 Jun; 53(12):1919-27. PubMed ID: 9256167
[TBL] [Abstract][Full Text] [Related]
11. Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis.
Hunter SA; Burstein SH
Life Sci; 1997; 60(18):1563-73. PubMed ID: 9126878
[TBL] [Abstract][Full Text] [Related]
12. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice.
Smith SR; Terminelli C; Denhardt G
J Pharmacol Exp Ther; 2000 Apr; 293(1):136-50. PubMed ID: 10734163
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid.
Calignano A; La Rana G; Makriyannis A; Lin SY; Beltramo M; Piomelli D
Eur J Pharmacol; 1997 Dec; 340(2-3):R7-8. PubMed ID: 9537804
[TBL] [Abstract][Full Text] [Related]
14. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain.
Burkey TH; Quock RM; Consroe P; Ehlert FJ; Hosohata Y; Roeske WR; Yamamura HI
Eur J Pharmacol; 1997 Oct; 336(2-3):295-8. PubMed ID: 9384246
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of 2-arachidonoyl glycerol in anesthetized mice.
Járai Z; Wagner JA; Goparaju SK; Wang L; Razdan RK; Sugiura T; Zimmer AM; Bonner TI; Zimmer A; Kunos G
Hypertension; 2000 Feb; 35(2):679-84. PubMed ID: 10679517
[TBL] [Abstract][Full Text] [Related]
16. Changes in rat brain energetic metabolism after exposure to anandamide or Delta(9)-tetrahydrocannabinol.
Costa B; Colleoni M
Eur J Pharmacol; 2000 Apr; 395(1):1-7. PubMed ID: 10781666
[TBL] [Abstract][Full Text] [Related]
17. Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)-tetrahydrocannabinol-induced inhibition of natural killer activity.
Massi P; Fuzio D; Viganò D; Sacerdote P; Parolaro D
Eur J Pharmacol; 2000 Jan; 387(3):343-7. PubMed ID: 10650181
[TBL] [Abstract][Full Text] [Related]
18. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide.
Houser SJ; Eads M; Embrey JP; Welch SP
Brain Res; 2000 Feb; 857(1-2):337-42. PubMed ID: 10700588
[TBL] [Abstract][Full Text] [Related]
19. Anandamide and delta 9-THC dilation of cerebral arterioles is blocked by indomethacin.
Ellis EF; Moore SF; Willoughby KA
Am J Physiol; 1995 Dec; 269(6 Pt 2):H1859-64. PubMed ID: 8594893
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid ligands and their effects on learning and performance in rhesus monkeys.
Winsauer PJ; Lambert P; Moerschbaecher JM
Behav Pharmacol; 1999 Sep; 10(5):497-511. PubMed ID: 10780256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
